MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Begin MULPLETA dosing 8-14 days prior to a scheduled procedure.
Patients should undergo their procedure 2-8 days after the last dose.
Recommended Dosage: 3 mg orally once daily with or without food for 7 days.
Tablets: 3 mg lusutrombopag as a light red, round, film-coated tablet debossed with the Shionogi trademark ( ) above the identifier code "551" on one side and with a "3" on the other side.
Lactation: Breastfeeding is not recommended during treatment.
None.
Thrombotic/Thromboembolic Complications: MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Monitor platelet counts and for thromboembolic events and institute treatment promptly.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available